Strategic Acquisition Pursuit Vascular became part of ICU Medical in November 2019, integrating the ClearGuard HD antimicrobial barrier caps into a broader medical device portfolio. This creates cross-sell opportunities for ICU Medical’s sales teams to reach dialysis centers and hospitals already familiar with Pursuit Vascular products.

Infection Prevention Focus The ClearGuard HD cap targets infection prevention by reducing CLABSIs in hemodialysis patients. This aligns with hospital quality initiatives and pay-for-performance programs, suggesting strong selling points around patient safety, outcomes, and potential hospital incentive programs.

Product Line Synergy ICU Medical’s emphasis on patient-centric, workflow-friendly products indicates sales messaging that can emphasize compatibility with existing catheter workflows and ease of adoption, reducing operational disruption for dialysis units.

Recent Financing & Growth Despite a modest revenue base (<$1M) and a funding round of $13M, the company's growth trajectory within ICU Medical’s portfolio could be leveraged to pursue partnerships, co-marketing, or grant-funded expansion in dialysis-related infection control.

Industry Engagement ICU Medical and Pursuit Vascular participate in major healthcare conferences and strategic partnerships (e.g., VisionHealth collaboration, J.P. Morgan Conference). Use these events to identify key hospitals, distributors, and KOLs for expanding adoption of infection-prevention caps and related products.